Use of HA 330-II for Hemofiltration in Patients With ALF as a Bridge to Liver Transplantation .

Last updated: January 24, 2020
Sponsor: Asian Institute of Gastroenterology, India
Overall Status: Active - Recruiting

Phase

4

Condition

Liver Disease

Liver Failure

Primary Biliary Cholangitis

Treatment

N/A

Clinical Study ID

NCT04243655
AIG-G/ALFLD
  • Ages 18-65
  • All Genders

Study Summary

ALF (ALF) is defined by three criteria: (1) rapid development of hepatocellular dysfunction (jaundice, coagulopathy), (2) hepatic encephalopathy, and (3) absence of a prior history of liver disease.

Interval between onset of acute hepatic injury (jaundice) and onset of liver failure (encephalopathy with or without coagulopathy) in such patients (icterus-encephalopathy interval; IEI) has been described to be between 4 weeks (Indian definition) to 24 weeks (AASLD-ALF study group). Further, due to the diverse natural course, ALF has been sub-classified as hyperacute (IEI ≤ 7 day), acute (IEI ≤ 4 weeks) and sub-acute ALF (IEI ≥ 5 week to ≤12 weeks) by British authors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Acute Liver Failure patients with SIRS and Hepatic Encephalopathy, withouthyperbilirubinemia.

Exclusion

Exclusion Criteria:

  • Patients with age less than 18 years or more than 65 years

  • Extremely moribund patients with an expected life expectancy of less than 24 hours orwith poor prognosis

  • With poor blood clotting function and PTA <30%.

  • Active Bleed

  • Chronic heart, lung or kidney disease

  • Malignant tumors including liver cancer

  • Past history of organ transplantation

Study Design

Total Participants: 10
Study Start date:
December 30, 2019
Estimated Completion Date:
December 31, 2020

Study Description

Since the 1960s, Liver Transplantation (LT) has emerged as a cornerstone intervention to cure liver failure. Mortality in patients with liver failure who cannot be rescued with Liver Transplantation remains high despite improvements in supportive care.

Artificial Liver Support System (ALSS) in ALF aim to remove excess inflammatory cytokines and attenuate inflammatory response, to remove albumin-bound and water-soluble toxins, to restore and preserve hepatic function and mitigate or limit the progression of multiorgan failure while hepatic recovery or liver transplant occurs. ALSS may also provide benefit in instances where LT is contraindicated.

The following beneficial effects have been documented with ALSS in ALF patients: improvement of jaundice, amelioration of hemodynamic instability, improvement of hepatic encephalopathy, SOFA score and survival.

HA 330-II is a broad-spectrum adsorbent made of neutral macroporous resin, removes toxins such as Inflammatory mediators (IL-1, IL-6, IL-8 & TNF-α) along with hepatic toxins such as phenol, mercaptan, aromatic amino acids, false neurotransmitters and indirectly ammonia by improving liver function recovery. However, this indirect ammonia removal with HA 330-II is insignificant. By removing excess inflammatory cytokines and attenuating uncontrolled immune response, HA 330-II prevents worsening of encephalopathy, improves liver function recovery and improves prognosis.

Connect with a study center

  • Asian Institute Of Gastroenterology

    Hyderabad, Telangana 500032
    India

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.